Sinalização PI3K/Akt/mTOR
Os inibidores da sinalização PI3K/Akt/mTOR são compostos que têm como alvo as vias da fosfoinositídeo 3-quinase (PI3K), da quinase Akt e do alvo da rapamicina em mamíferos (mTOR). Essas vias são reguladores críticos do crescimento celular, sobrevivência, metabolismo e autofagia, tornando-os alvos-chave na pesquisa de câncer e distúrbios metabólicos. A inibição dessas vias pode ajudar a controlar o crescimento e a proliferação tumoral, oferecendo estratégias terapêuticas potenciais para vários tipos de câncer e outras doenças caracterizadas por sinalização celular desregulada. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de alta qualidade de PI3K/Akt/mTOR para apoiar sua pesquisa em oncologia, sinalização celular e doenças metabólicas.
Subcategorias de "Sinalização PI3K/Akt/mTOR"
- AMPK(158 produtos)
- ATM/ATR(71 produtos)
- DNA-PK(51 produtos)
- EGFR(572 produtos)
- MELK(7 produtos)
- PDK(9 produtos)
- PI3K(242 produtos)
- S6 Quinase(9 produtos)
- gsk-3(112 produtos)
- mTOR(144 produtos)
Exibir 2 mais subcategorias
Foram encontrados 1038 produtos de "Sinalização PI3K/Akt/mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Epitinib succinate
CAS:<p>Epitinib succinate (HMPL-813 succinate) is an orally active and brain penetration EGFR tyrosine kinase inhibitor and can be used in studies about cancer.</p>Fórmula:C28H32N6O6Pureza:98.02% - 99.79%Cor e Forma:SolidPeso molecular:548.59JR-AB2-011
CAS:<p>JR-AB2-011: selective mTORC2 inhibitor, IC50 = 0.36μM, blocks Rictor-mTOR, Ki = 0.19μM, cytotoxic in glioblastoma.</p>Fórmula:C17H14Cl2FN3OSPureza:98.33% - 98.33%Cor e Forma:SolidPeso molecular:398.28Falnidamol
CAS:<p>Falnidamol (BIBX 1382), an oral selective EGFR inhibitor, IC50 3 nM, weak on ErbB2 and others, anti-cancer pyrimido-pyrimidine.</p>Fórmula:C18H19ClFN7Pureza:98.816%Cor e Forma:SolidPeso molecular:387.84EGFR-IN-9
CAS:<p>EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M).</p>Fórmula:C29H24N4O3Pureza:99.8%Cor e Forma:SolidPeso molecular:476.53Cloperastine fendizoate
CAS:<p>Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).</p>Fórmula:C40H38ClNO5Pureza:99.97%Cor e Forma:SolidPeso molecular:648.19GS-9901
CAS:<p>GS-9901 is a selective, orally active and potent PI3Kδ inhibitor (IC50: 1 nM) for the study of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.</p>Fórmula:C22H17ClFN9OPureza:98.60% - 99.92%Cor e Forma:SolidPeso molecular:477.88EGFR-IN-99
CAS:<p>EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor for the study of non-small cell lung cancer (NSCLC).</p>Fórmula:C25H22FN7O3Pureza:97.75%Cor e Forma:SolidPeso molecular:487.49A-935142
CAS:<p>A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.</p>Fórmula:C18H19F3N2O2Pureza:98.97% - 99.91%Cor e Forma:SolidPeso molecular:352.35EMI1
CAS:<p>EMI1 targets mutated EGFR in drug-resistant NSCLC research.</p>Fórmula:C20H18N2O3Pureza:99.96%Cor e Forma:SolidPeso molecular:334.37PD 174265
CAS:<p>PD 174265 is an effective, selective and reversible inhibitor of epidermal growth factor receptor (EGFR) with an IC50 of 0.45 nM.</p>Fórmula:C17H15BrN4OPureza:99.51%Cor e Forma:SolidPeso molecular:371.23GSK-3β inhibitor 11
CAS:<p>GSK-3β inhibitor 11 (compound 21) is a potent inhibitor of glycogen synthase kinase-3β (GSK-3β) with an inhibitory concentration (IC50) of 10.02 μM.</p>Fórmula:C20H15N3O4SPureza:97.33%Cor e Forma:SolidPeso molecular:393.42Tyrphostin A25
CAS:<p>Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.</p>Fórmula:C10H6N2O3Pureza:98.76%Cor e Forma:Yellow Green Powder /Off-White SolidPeso molecular:202.17SKLB 1028
CAS:<p>SKLB 1028, an oral EGFR/FLT3/Abl inhibitor, excels in AML and CML with Abl mutations.</p>Fórmula:C24H29N9Pureza:99.90% - >99.99%Cor e Forma:SolidPeso molecular:443.55CGP77675
CAS:<p>CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and</p>Fórmula:C26H29N5O2Pureza:99.66%Cor e Forma:SolidPeso molecular:443.54BIP-135
CAS:<p>BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor.</p>Fórmula:C21H13BrN2O3Pureza:99.93%Cor e Forma:SolidPeso molecular:421.24ARN25068
CAS:<p>ARN25068 inhibits GSK-3β, FYN, DYRK1A kinases; acts in sub-micromolar range; combats tau hyperphosphorylation.</p>Fórmula:C19H18N6SPureza:99.75%Cor e Forma:SolidPeso molecular:362.45LY 456236 hydrochloride
CAS:<p>LY 456236 hydrochloride (MPMQ hydrochloride) is an mGlu1 receptor antagonist with an ic50 value of 143 nM.</p>Fórmula:C16H16ClN3O2Pureza:99.95%Cor e Forma:SolidPeso molecular:317.77GSK-3 Inhibitor XIII
CAS:<p>GSK-3 InhibitorXIII, an ATP-competitive GSK-3 inhibitor (Ki: 24 nM), can be used to study diabetes and obesity.</p>Fórmula:C18H15N5Pureza:99.85% - 99.86%Cor e Forma:SolidPeso molecular:301.35Larotinib
CAS:<p>Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.</p>Fórmula:C24H26ClFN4O4Pureza:98.45%Cor e Forma:SolidPeso molecular:488.94AZ044
CAS:<p>AZ044 is a potent, selective inhibitor of type III phosphatidylinositol-4-kinase alpha-subtype (PI4KIIIalpha).</p>Fórmula:C24H27N3O3SPureza:99.5%Cor e Forma:SolidPeso molecular:437.55YKL-06-062
CAS:<p>YKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor that inhibits SIK1, SIK2 and SIK3 with IC50s of 2.12 nM, 1.40 nM and 2.86 nM.</p>Fórmula:C31H39N7OPureza:99.87%Cor e Forma:SolidPeso molecular:525.69PQR514
CAS:<p>PQR514: more potent pan-PI3K inhibitor than predecessor PQR309, exhibits strong anticancer activity in vitro and in OVCAR-3 model.</p>Fórmula:C16H20F2N8O2Pureza:98.77% - 99.19%Cor e Forma:SolidPeso molecular:394.38MELK-8a hydrochloride
CAS:<p>MELK-8a hydrochloride is a potent inhibitor of maternal embryonic leucine zipper kinase (MELK, IC50 = 2 nM). </p>Fórmula:C25H33ClN6OPureza:99.87%Cor e Forma:SolidPeso molecular:469.02PKI-166
CAS:<p>PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.</p>Fórmula:C20H18N4OPureza:99.2%Cor e Forma:SolidPeso molecular:330.38RS1-PDK1 inhibitor
CAS:<p>RS1-PDK1 inhibitor (RS 1) is a selective inhibitor of the protein kinase PDK1 that can be used to treat and prevent disease or disorders.</p>Fórmula:C15H9ClN2O2S3Pureza:98.12%Cor e Forma:SolidPeso molecular:380.89TGX-115
CAS:<p>TGX-115 inhibits PI 3-K p110β (IC50=0.13μM) & p110δ (IC50=0.63μM), treats various cardiovascular diseases.</p>Fórmula:C20H20N2O3Pureza:99.48%Cor e Forma:SolidPeso molecular:336.38Rezivertinib
CAS:<p>Rezivertinib (BPI-7711) is an EGFR inhibitor with antitumor activity and can be used to study central nervous system diseases.</p>Fórmula:C27H30N6O3Pureza:99.26% - 99.89%Cor e Forma:SolidPeso molecular:486.57NVP-BAG956
CAS:<p>NVP-BAG956 is an ATP-competitive PI3K inhibitor (IC50s: 34/56/112/444 nM for PI3Kδ/PI3Kα/PI3Kγ/PI3Kβ).</p>Fórmula:C28H21N5Pureza:99.25% - 99.80%Cor e Forma:SolidPeso molecular:427.5(R)-(-)-Rolipram
CAS:<p>(R)-(-)-Rolipram ((-)-Rolipram) is an R-enantiomer of Rolipram which is a PDE4 inhibitor.</p>Fórmula:C16H21NO3Pureza:99.54%Cor e Forma:SolidPeso molecular:275.34PF-249
CAS:<p>PF-249 (PF-06685249) is a β1-selective AMPK with an EC50 of 12 nM for AMPK α1β1γ1 and can be used in studies about diabetic nephropathy.</p>Fórmula:C17H16ClN3O3Pureza:97.01%Cor e Forma:SolidPeso molecular:345.78SRX3207
CAS:<p>SRX3207 is an inhibitor of Syk and PI3K and relieves tumor immunosuppression.</p>Fórmula:C29H29N7O3SPureza:99.85%Cor e Forma:SolidPeso molecular:555.65GSK-3β inhibitor 2
CAS:<p>GSK-3β inhibitor 2 (5-Thiazolecarboxamide,2-[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]-4-methoxy-) is a BBB-crossing and selective inhibitor of GSK-3β (IC50</p>Fórmula:C14H14N4O3SPureza:99.08%Cor e Forma:SolidPeso molecular:318.35YLF-466D
CAS:<p>YLF-466D (C24) is a newly developed AMPK activator, which inhibits platelet aggregation.</p>Fórmula:C29H20ClNO3Pureza:97.74%Cor e Forma:SolidPeso molecular:465.93Sunvozertinib
CAS:<p>Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2.Cost-effective and quality-assured.</p>Fórmula:C29H35ClFN7O3Pureza:98.11% - 99.63%Cor e Forma:SolidPeso molecular:584.08ABC1183
CAS:<p>ABC1183, an oral diaminothiazole, inhibits GSK3α/β, CDK9, hinders cancer cell growth, induces G2/M arrest, and modulates phosphorylation.</p>Fórmula:C18H14N4OSPureza:98.92%Cor e Forma:SolidPeso molecular:334.39(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Fórmula:C16H14N2O2Cor e Forma:SolidPeso molecular:266.29PI3Kδ-IN-17
CAS:<p>PI3Kδ-IN-17 (Compound S5) is a potent PI3K δ inhibitor, exhibiting an IC50 value of 2.82 nM and demonstrates significant efficacy in suppressing the</p>Fórmula:C23H24F3N7O2Pureza:98%Cor e Forma:SolidPeso molecular:487.48MTI-31
CAS:<p>MTI-31 (LXI-15029) is a potent oral mTORC1/2 inhibitor with a Kd of 0.20 nM, >5,000-fold selectivity, and an IC50 of 39 nM.</p>Fórmula:C26H30N6O3Pureza:99.97%Cor e Forma:SolidPeso molecular:474.55PI3K/mTOR Inhibitor-14
CAS:<p>PI3K/mTOR Inhibitor-14 (compound Y-2) serves as a dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 171.4 nM and 10.1 nM , respectively, and</p>Fórmula:C28H30N8O3SPureza:98%Cor e Forma:SolidPeso molecular:558.66PI3K/mTOR Inhibitor-7
CAS:<p>Potent PI3K/mTOR inhibitor, 4.7x stronger than gedatolisib; IC50: 1.4 μM (PI3K), 0.3 μM (mTOR); impacts PI3K/Akt/mTOR pathway; research in cancer.</p>Fórmula:C29H33N9O4Cor e Forma:SolidPeso molecular:571.63LAS191954
CAS:<p>LAS191954 is a selective, potent and orally active PI3Kδ inhibitor for inflammatory diseases treatment(IC50 : 2.6 nM).</p>Fórmula:C20H15N9OPureza:98%Cor e Forma:SolidPeso molecular:397.39MIPS-21335
CAS:<p>MIPS-21335 is a potent PI3KC2α inhibitor with an IC50 value of 7 nM and additionally exhibits inhibitory activity against PI3KC2β, p110α, p110β, and p110δ with</p>Fórmula:C24H21N7O5Pureza:98%Cor e Forma:SolidPeso molecular:487.47MP7
CAS:<p>MP7 (PDK1 inhibitor) is a inhibitor of phosphoinositide-dependent kinase-1 (PDK1).</p>Fórmula:C28H22F2N4O4Pureza:99.84% - 99.89%Cor e Forma:SolidPeso molecular:516.5ZL-2201
CAS:<p>ZL-2201 is a potent inhibitor of DNA-PK, demonstrating an IC50 value of 1 nM.</p>Fórmula:C20H25N9O5SPureza:98%Cor e Forma:SolidPeso molecular:503.54EGFR-IN-1
CAS:<p>EGFR-IN-1: an oral, irreversible EGFR inhibitor targeting L858R/T790M mutations with high selectivity, showing potent antitumor effects.</p>Fórmula:C28H30N6O4Pureza:98%Cor e Forma:SolidPeso molecular:514.58MSC2360844
CAS:<p>MSC2360844 is a potent, orally active and selective inhibitor of PI3Kδ(IC50 of 145 nM).</p>Fórmula:C26H27FN4O5SPureza:99.54% - 99.9%Cor e Forma:SolidPeso molecular:526.58SAR-260301
CAS:<p>SAR-260301 is an orally available and selective inhibitor of PI3Kβ (IC50: 23 nM).</p>Fórmula:C19H22N4O3Pureza:99.74%Cor e Forma:SolidPeso molecular:354.4EGFR-IN-33
CAS:<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Fórmula:C26H25ClN6O2Cor e Forma:SolidPeso molecular:488.97PIK-inhibitors
CAS:<p>PIK-inhibitors (MDK34597) is a pan PI3K inhibitors, an analog of PI-103.</p>Fórmula:C19H17N5O2Pureza:96.98%Cor e Forma:SolidPeso molecular:347.37EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Fórmula:C16H9ClIN3Cor e Forma:SolidPeso molecular:405.62PI5P4K-β-IN-1
CAS:<p>PI5P4K-β-IN-1 (compound vs1) is a potent PI5P4K-β inhibitor with an IC50 of 0.80 μM [1].</p>Fórmula:C23H17Cl2N3O2Cor e Forma:SolidPeso molecular:438.31BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Fórmula:C22H25BrN4O2Pureza:99.02%Cor e Forma:SolidPeso molecular:457.36Tenalisib R Enantiomer
CAS:<p>Tenalisib R Enantiomer is an R enantiomer of Tenalisib .</p>Fórmula:C23H18FN5O2Pureza:98%Cor e Forma:SolidPeso molecular:415.42JND3229
CAS:<p>JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.</p>Fórmula:C33H41ClN8O2Pureza:98.75%Cor e Forma:SolidPeso molecular:617.18mTOR inhibitor-11
CAS:<p>mTOR inhibitor-11 (Compound 9) is a brain-penetrant compound capable of inhibiting mTOR with an IC50 of 21 nM for pS6.</p>Fórmula:C21H26N6O2Pureza:98%Cor e Forma:SolidPeso molecular:394.47DNA-PK-IN-10
CAS:<p>DNA-PK-IN-10 is a DNA-PK inhibitor utilized in the research of breast cancer and non-small cell lung cancer [1].</p>Fórmula:C25H28N6O2Pureza:98%Cor e Forma:SolidPeso molecular:444.53BRD5648
CAS:<p>BRD5648 ((R)-BRD0705) is an inactive (R)-enantiomer of BRD0705.</p>Fórmula:C20H23N3OPureza:99.89%Cor e Forma:SolidPeso molecular:321.42GNE-490
CAS:<p>GNE-490 is an effective inhibitor of pan-PI3K with IC50s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively.</p>Fórmula:C18H22N6O2SPureza:99.77%Cor e Forma:SolidPeso molecular:386.47TCS 21311
CAS:<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Fórmula:C27H25F3N4O4Pureza:99.39% - ≥98%Cor e Forma:SolidPeso molecular:526.51LDHA/PDKs-IN-1
CAS:<p>Compound 20e inhibits PDKs (IC50: 0.8 μM) & LDHA (IC50: 0.15 μM), halts A549 cell growth, lowers lactate, boosts oxygen use.</p>Fórmula:C19H21FN2O4Cor e Forma:SolidPeso molecular:360.38(Rac)-BRD0705
CAS:<p>(Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is an effective and selective inhibitor of GSK3α.</p>Fórmula:C20H23N3OPureza:99.7%Cor e Forma:SolidPeso molecular:321.42MS 154
CAS:<p>MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.</p>Fórmula:C46H54ClFN8O8Cor e Forma:SolidPeso molecular:901.42WYE-23
CAS:<p>WYE-23 is an inhibitor of mammalian target of rapamycin (mTOR).</p>Fórmula:C26H32N8O4Cor e Forma:SolidPeso molecular:520.58T-00127_HEV1
CAS:<p>T-00127_HEV1 is an inhibitor of phosphatidylinositol 4-kinase III beta(PI4KIIIβ, IC50 = 60 nM).</p>Fórmula:C22H29N5O3Pureza:99.89%Cor e Forma:SolidPeso molecular:411.5mTOR inhibitor 9d
CAS:<p>mTOR inhibitor 9d is a dual inhibitor of the protein kinases mTOR and PI3K with an mTOR IC50 value of 0.31 nm, and can be used for the treatment of leukemia,</p>Fórmula:C21H23N5O3SPureza:99.08%Cor e Forma:SoildPeso molecular:425.517β-Hydroxywortmannin
CAS:<p>17β-Hydroxywortmannin is an orally active phosphatidylinositol-3-kinase (PI-3-kinase) inhibitor, exhibiting an IC50 of 0.5 nM and notably suppresses osteoclast resorption at an IC50 of 10 nM. Additionally, it demonstrates antitumor activity.</p>Fórmula:C23H26O8Cor e Forma:SolidPeso molecular:430.45EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Fórmula:C32H28BrF3N6O4SCor e Forma:SolidPeso molecular:729.57mTOR inhibitor 9b
CAS:<p>mTOR inhibitor 9b is an enzyme inhibitor of protein kinase mTOR he phosphatidylinositol 3-kinase PIK3CA with IC50s of 0.76 nm and 1.262 µM, respectively.mTOR</p>Fórmula:C21H23N5O2SPureza:99.52%Cor e Forma:SoildPeso molecular:409.5Dezapelisib
CAS:<p>Dezapelisib, an oral delta PI3K inhibitor, blocks PIP3 production and PI3K/AKT pathway, hindering tumor cell growth and survival.</p>Fórmula:C20H16FN7OSCor e Forma:SolidPeso molecular:421.45Labuxtinib
CAS:<p>Labutinib is a selective inhibitor of the c-kit tyrosine kinase [1].</p>Fórmula:C20H16FN5O2Pureza:99.77%Cor e Forma:SolidPeso molecular:377.37SU-11752
CAS:<p>SU-11752 selectively inhibits DNA-PK by competing with ATP, enhances ionizing radiation sensitivity without affecting cell cycle or ATM activity.</p>Fórmula:C26H27N3O5SCor e Forma:SolidPeso molecular:493.57PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Fórmula:C23H18ClF2N3O2SPureza:98.84%Cor e Forma:SolidPeso molecular:473.92BMS-599626 Hydrochloride
CAS:<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Fórmula:C27H28ClFN8O3Pureza:99.98%Cor e Forma:SolidPeso molecular:567.01ZLN024
CAS:<p>ZLN024 is an activator of AMPK allosteric.</p>Fórmula:C13H13BrN2OSPureza:99.751%Cor e Forma:SolidPeso molecular:325.22PI3K/mTOR Inhibitor-1
CAS:<p>PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual inhibitor of PI3K/mTOR (PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ/mTOR with IC50s of 20/376/204/46/186 nM)</p>Fórmula:C18H22FN5O3SPureza:98%Cor e Forma:SolidPeso molecular:407.46CAL-130 Racemate
CAS:<p>CAL-130 Racemate is the racemate of CAL-130. CAL-130 is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).</p>Fórmula:C23H22N8OPureza:98%Cor e Forma:SolidPeso molecular:426.47HKI-357
CAS:<p>HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.</p>Fórmula:C31H29ClFN5O3Pureza:99.91%Cor e Forma:SolidPeso molecular:574.05PF-06459988
CAS:<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Fórmula:C19H22ClN7O3Pureza:98%Cor e Forma:SolidPeso molecular:431.88mTOR inhibitor-3
CAS:<p>mTOR inhibitor-3 is a selective mTOR inhibitor (Ki= 1.5 nM). mTOR inhibitor-3 inhibits mTORC1 and mTORC2 in cellular and in vivo experiments.</p>Fórmula:C25H30N8O2Pureza:99% - 99.64%Cor e Forma:SolidPeso molecular:474.56Zandelisib
CAS:<p>Zandelisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K)(p110δ, IC50 of 3.5 nM), and with antineoplastic activity.</p>Fórmula:C31H38F2N8OPureza:99.88%Cor e Forma:SolidPeso molecular:576.68Alpelisib hydrochloride
CAS:<p>Alpelisib hydrochloride (BYL-719) is an oral, selective PI3Kα inhibitor with anticancer properties.</p>Fórmula:C19H23ClF3N5O2SPureza:98%Cor e Forma:SolidPeso molecular:477.93PI3Kδ-IN-1
CAS:<p>PI3Kδ-IN-1 is an efficacious PI3Kδ inhibitor (IC50 of 1.7 nM).</p>Fórmula:C22H20F3N7O2Pureza:99.85%Cor e Forma:SolidPeso molecular:471.44EGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Fórmula:C36H46BrN8O2PCor e Forma:SolidPeso molecular:733.685-Iodo-indirubin-3'-monoxime
CAS:<p>5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50s</p>Fórmula:C16H10IN3O2Cor e Forma:SolidPeso molecular:403.17Ampkinone
CAS:<p>Ampkinone is an indirect AMPK activator.</p>Fórmula:C31H23NO6Pureza:98%Cor e Forma:SolidPeso molecular:505.52BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Fórmula:C16H12BrN5Cor e Forma:SolidPeso molecular:354.2LDHA/PDKs-IN-2
CAS:<p>Compound 20k is a dual LDHA/PDKs inhibitor; IC50: 0.7/1.6 μM. It boosts O2 use, cuts lactate, and slows A549 cancer cell growth (EC50: 15.7 μM).</p>Fórmula:C17H20N2O5Cor e Forma:SolidPeso molecular:332.35PI3K/mTOR Inhibitor-6
CAS:<p>Potent, stable PI3K/mTOR Inhibitor-6 surpasses gedatolisib in gastric fluid; 10 μM hinders PI3K/Akt/mTOR pathway, aids cancer research.</p>Fórmula:C30H34N10O4Cor e Forma:SolidPeso molecular:598.66NVP-QAV-572
CAS:<p>NVP-QAV-572 is a inhibitor of PI3K(IC50 of 10 nM).</p>Fórmula:C17H19F2N7O3S2Pureza:98%Cor e Forma:SolidPeso molecular:471.5Lifirafenib
CAS:<p>Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant</p>Fórmula:C25H17F3N4O3Pureza:98% - 98.25%Cor e Forma:SolidPeso molecular:478.42SAR502250
CAS:<p>SAR502250: potent, selective GSK3 inhibitor, IC50=12nM, oral, brain-penetrant, potential for AD research, antidepressant-like properties.</p>Fórmula:C19H18FN5O2Cor e Forma:SolidPeso molecular:367.38HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Fórmula:C27H33N7O3Cor e Forma:SolidPeso molecular:503.6CC214-1
CAS:<p>CC214-1 is an mTOR inhibitor that inhibits protein translation, induces autophagy, and is an in vitro tool compound for exploring the biology of mTOR kinases.</p>Fórmula:C20H21N7O2Pureza:97.16%Cor e Forma:SolidPeso molecular:391.43Antitrypanosomal agent 14
CAS:<p>Antitrypanosomal agent 14 (Compound 1), a potent T.</p>Fórmula:C14H23N3OSPureza:98%Cor e Forma:SolidPeso molecular:281.42A 1070722
CAS:<p>A 1070722: potent GSK-3 inhibitor, Ki = 0.6 nM for both α/β isoforms, crosses BBB, potential brain GSK-3 PET radiotracer.</p>Fórmula:C17H13F3N4O2Pureza:99.9%Cor e Forma:SolidPeso molecular:362.31PT-65
CAS:<p>PT-65, a potent and selective GSK3 degrader, demonstrates the highest degradation capacity for GSK3α (DC50 = 28.3 nM) and GSK3β (DC50 = 34.2 nM) in SH-SY5Y cells, making it applicable for Alzheimer's disease research [1].</p>Fórmula:C51H63N13O12SCor e Forma:SolidPeso molecular:1082.19PI5P4Kα-IN-1
CAS:<p>PI5P4Kα-IN-1 (Compound 13) is a phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) inhibitor, displaying IC50 values of 2 μM for PI5P4Kα and 9.4 μM for PI5P4Kβ</p>Fórmula:C20H17N3O2SPureza:98%Cor e Forma:SolidPeso molecular:363.43PI3K/mTOR Inhibitor-5
CAS:<p>PI3K/mTOR Inhibitor-5 is a potent dual inhibitor of PI3K and mTOR, displaying IC50 values of 86.9 nM (for PI3K) and 14.6 nM (for mTOR), respectively.</p>Fórmula:C32H40N10O3Cor e Forma:SolidPeso molecular:612.73Nazartinib S-enantiomer
CAS:<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Fórmula:C26H31ClN6O2Pureza:98%Cor e Forma:SolidPeso molecular:495.02PI3Kγ inhibitor 2
CAS:<p>PI3Kγ inhibitor 2 is an orally bioavailable inhibitor of PI3Kγ(Ki of 4 nM).</p>Fórmula:C20H18F3N5O3Pureza:98%Cor e Forma:SolidPeso molecular:433.38BX-320
CAS:<p>BX-320, a PDK1 inhibitor (IC50=30nM), selectively blocks Akt/p70S6K1 phosphorylation, induces apoptosis, and inhibits cancer cell growth.</p>Fórmula:C23H31BrN8O3Cor e Forma:SolidPeso molecular:547.45BEBT-109
CAS:<p>BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.</p>Fórmula:C27H32N8O3Pureza:97.26%Cor e Forma:SolidPeso molecular:516.6EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Fórmula:C28H33BrN7O2PCor e Forma:SolidPeso molecular:610.49EGFR-IN-61
CAS:<p>EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).</p>Fórmula:C33H37ClN8O3Pureza:98%Cor e Forma:SolidPeso molecular:629.15EGFR-IN-85
CAS:<p>EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR</p>Fórmula:C26H30N8O2Pureza:98%Cor e Forma:SolidPeso molecular:486.57JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Fórmula:C22H23BrFN5O2Pureza:98%Cor e Forma:SolidPeso molecular:488.35PI3K/mTOR Inhibitor-12
CAS:<p>PI3K/mTOR Inhibitor-12: oral, potent, selective; IC50: PI3Kα 0.06 nM, mTOR 3.12 nM; strong antitumor; less liver toxicity.</p>Fórmula:C27H27F2N9O4SPureza:98%Cor e Forma:SolidPeso molecular:611.62Simotinib
CAS:<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Fórmula:C25H26ClFN4O4Pureza:99.7%Cor e Forma:SolidPeso molecular:500.95EGFR/CSC-IN-1
CAS:<p>EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potential</p>Fórmula:C54H54Cl2FN7O7S2Pureza:98%Cor e Forma:SolidPeso molecular:1067.082′-Thioadenosine
CAS:<p>2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against</p>Fórmula:C10H13N5O3SPureza:98%Cor e Forma:SolidPeso molecular:283.31DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Fórmula:C28H27F2N7O3Pureza:98%Cor e Forma:SolidPeso molecular:547.56EGFR mutant-IN-1
<p>EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.</p>Fórmula:C34H39ClFN7O2Pureza:98%Cor e Forma:SolidPeso molecular:632.17GSK-3β inhibitor 8
CAS:<p>GSK-3β inhibitor 8 (GSK3β Inhibitor XVIII) is a potent and selective GSK-3β inhibitor with an IC50 value of 64 nM.GSK-3β inhibitor 8 is a thienopyrimidine</p>Fórmula:C20H20ClN5OSPureza:98.46%Cor e Forma:SolidPeso molecular:413.92EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Fórmula:C26H25ClN6O2Cor e Forma:SolidPeso molecular:488.97EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Fórmula:C31H34N6O3Cor e Forma:SolidPeso molecular:538.64AMPK-α1β1γ1 activator 1
CAS:<p>AMPK-α1β1γ1 activator 1 (M1), an acyl glucuronide metabolite derived from an Indole-3-carboxylic Acid-based AMPK activator, selectively activates the β1</p>Fórmula:C25H24ClNO9Pureza:98%Cor e Forma:SolidPeso molecular:517.91EGFR-IN-87
CAS:<p>EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,</p>Fórmula:C28H33N7O2Pureza:98.64%Cor e Forma:SolidPeso molecular:499.61EGFR-IN-1 hydrochloride
CAS:<p>EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.</p>Fórmula:C28H31ClN6O4Pureza:99.16%Cor e Forma:SolidPeso molecular:551.04BGB-8035
CAS:<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Fórmula:C24H31N5O4Pureza:96.74%Cor e Forma:SolidPeso molecular:453.53EGFR/ErbB-2 inhibitor-1
CAS:<p>EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.</p>Fórmula:C23H15ClFN3OS2Pureza:98.93%Cor e Forma:SolidPeso molecular:467.97Sevabertinib
CAS:<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Fórmula:C24H25ClN4O5Pureza:99.81%Cor e Forma:SolidPeso molecular:484.93Rheb inhibitor NR1
CAS:<p>Rheb inhibitor NR1 is a Rheb inhibitor and selective mTORC1 inhibitor that promotes phosphorylation of S473pAKT.</p>Fórmula:C25H19BrCl2N2O3SPureza:99.72%Cor e Forma:SolidPeso molecular:578.3PI3K-IN-54
CAS:<p>Compound 10w, a substituted pyrazolo[1,5-a]pyrimidinamide compound, is a ZSTK474 analog that shows anticancer activity against HeLa cells.</p>Fórmula:C20H24F2N8O3Pureza:98.15%Cor e Forma:SolidPeso molecular:462.45GSK-F1
CAS:<p>GSK-F1 (PI4KA inhibitor-F1) is a novel potent PI4KA inhibitor.</p>Fórmula:C27H18F5N5O4SPureza:97.03%Cor e Forma:SolidPeso molecular:603.52PF-04979064
CAS:<p>PF-04979064 is a potent and selective PI3K and mTOR dual kinase inhibitor(Ki of 0.13 nM and 1.42 nM,respectively).</p>Fórmula:C24H26N6O3Pureza:98.20% - ≥98%Cor e Forma:SolidPeso molecular:446.5PKI-402
CAS:<p>PKI-402 is a potent PI3K and mTOR inhibitor. PKI-402 inhibits PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ with IC50s of 2, 3, 7, 14 and 16 nM, respectively.</p>Fórmula:C29H34N10O3Pureza:99.94%Cor e Forma:SolidPeso molecular:570.65GSK-3 inhibitor 1
CAS:<p>GSK-3 inhibitor 1 is a GSK-3 inhibitor.</p>Fórmula:C22H17ClFN5O2Pureza:98.42%Cor e Forma:SolidPeso molecular:437.85EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Fórmula:C32H23ClF3N7O4Pureza:99.51%Cor e Forma:SolidPeso molecular:662.02GDC-0349
CAS:<p>GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.</p>Fórmula:C24H32N6O3Pureza:96.00% - 98.17%Cor e Forma:SolidPeso molecular:452.55GLPG3312
CAS:<p>GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .</p>Fórmula:C23H21F2N5O3Pureza:98.53%Cor e Forma:SolidPeso molecular:453.44EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Fórmula:C14H11BrN4O2SCor e Forma:SolidPeso molecular:379.23DNA-PK-IN-15
CAS:<p>DNA-PK-IN-15 (compound 6) acts as an inhibitor of DNA-PK, exhibiting an IC50 value of 0.08 nM.</p>Fórmula:C23H23N9OCor e Forma:SolidPeso molecular:441.49HER2-IN-7
CAS:<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Fórmula:C28H26F3N7O3Cor e Forma:SolidPeso molecular:565.55EGFR-IN-160
CAS:<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Fórmula:C15H12N2O4Cor e Forma:SolidPeso molecular:284.27EGFR/HER2-IN-4
<p>EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.</p>Cor e Forma:SolidEGFR-IN-147
CAS:<p>EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.</p>Fórmula:C13H13N5OCor e Forma:SolidPeso molecular:255.275EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Fórmula:C24H15FO3Cor e Forma:SolidPeso molecular:370.37EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Fórmula:C27H25N3O6SCor e Forma:SolidPeso molecular:519.57LAS195319
CAS:<p>LAS195319 is a potent and selective inhaled PI3Kδ Inhibitor (IC50 = 0.5 nM) for the Treatment of Respiratory Diseases.</p>Fórmula:C29H26N10O3SCor e Forma:SolidPeso molecular:594.65EGFR-IN-23
CAS:<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Fórmula:C36H44BrN10O3PCor e Forma:SolidPeso molecular:775.68iMDK quarterhydrate
<p>iMDK quarterhydrate, PI3K inhibitor, blocks MDK growth; suppresses NSCLC safely with MEK inhibitor.</p>Fórmula:C21H15FN2O3SCor e Forma:SolidPeso molecular:380.91ES-072
CAS:<p>ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.</p>Fórmula:C25H27F3N8O2Cor e Forma:SolidPeso molecular:528.53EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Fórmula:C31H30FN7OCor e Forma:SolidPeso molecular:535.61Tesevatinib tosylate
CAS:<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Fórmula:C31H33Cl2FN4O5SCor e Forma:SolidPeso molecular:663.59PI3Kδ-IN-23
CAS:<p>PI3Kδ-IN-23 (compound A11) is a potent inhibitor of PI3Kδ, with an IC50 of 0.27 nM. It binds to PI3Kδ through covalent interaction with Lys779 and plays a significant role in cancer research.</p>Fórmula:C30H30N6O5Cor e Forma:SolidPeso molecular:554.596DNA-PK-IN-6
CAS:<p>DNA-PK-IN-6 inhibits DNA-PKcs, disrupting tumor DNA repair and triggering apoptosis; enhances radiotherapy and targets various tumors (WO2021197159A1).</p>Fórmula:C19H21N7OCor e Forma:SolidPeso molecular:363.42EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Fórmula:C26H28ClN3O4Cor e Forma:SolidPeso molecular:481.975-Bromo-3-indoxylacetate
CAS:<p>5-Bromo-3-indoxylacetate acts as an inhibitor of GSK-3, with a pIC50 value of 3.39.</p>Fórmula:C10H8BrNO2Cor e Forma:SolidPeso molecular:254.08HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Fórmula:C19H14BrF3N2OCor e Forma:SolidPeso molecular:423.23DNA-PK-IN-8
CAS:<p>DNA-PK-IN-8: Potent, selective oral DNA-PK inhibitor, IC50 = 0.8 nM, boosts anti-cancer effects with Doxorubicin.</p>Fórmula:C19H22N8O2Cor e Forma:SolidPeso molecular:394.43Andamertinib
CAS:<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Fórmula:C31H36N8O3Cor e Forma:SolidPeso molecular:568.669EGFR-IN-135
<p>EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.</p>Fórmula:C12H14N4OS2Cor e Forma:SolidPeso molecular:294.4Tyrphostin 63
CAS:<p>Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.</p>Fórmula:C10H8N2OCor e Forma:SolidPeso molecular:172.183EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Fórmula:C30H26N8OCor e Forma:SolidPeso molecular:514.58PI3K-IN-27
CAS:<p>PI3K-IN-27 is a potent PI3K inhibitor, relevant for cancer and immune disease research. See patent WO2021233227A1.</p>Fórmula:C30H26F2N6O2SCor e Forma:SolidPeso molecular:572.63PI3Kβ-IN-1
CAS:<p>PI3Kβ-IN-1 is a selective, orally active PI3Kβ inhibitor (IC50: 2 nM).</p>Fórmula:C25H14F2N8Cor e Forma:SolidPeso molecular:464.43ETP-47037
CAS:<p>ETP-47037: strong PI3Kα inhibitor (IC50: 0.99 nM), also targets PI3Kβ, δ, γ; may protect telomeres.</p>Fórmula:C20H27N9O3SCor e Forma:SolidPeso molecular:473.55GSK3-IN-9
CAS:<p>GSK3-IN-9 (0713) is a selective inhibitor of glycogen synthase kinase 3 (GSK3). It holds potential for research into fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood epilepsy, intellectual disabilities, diabetes, acute myeloid leukemia (AML), autism, and mental disorders.</p>Fórmula:C18H20N4OCor e Forma:SolidPeso molecular:308.378EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Cor e Forma:SolidEGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Fórmula:C26H27ClN6O2Cor e Forma:SolidPeso molecular:490.98PI3K-IN-26
CAS:<p>PI3K-IN-26 is an effective PI3K inhibitor. PI3K-IN-26 inhibits the proliferation of SU-DHL-6 cells, IC50= 36 nM.</p>Fórmula:C21H18N6OSCor e Forma:SolidPeso molecular:402.47EGFR-IN-133
CAS:<p>EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.</p>Fórmula:C27H29F2N7O3Cor e Forma:SolidPeso molecular:537.56EGFR-IN-132
CAS:<p>EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.</p>Fórmula:C27H31N7O3Cor e Forma:SolidPeso molecular:501.58EGFR-IN-139
CAS:<p>EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).</p>Fórmula:C27H25ClN2O4Cor e Forma:SolidPeso molecular:476.951Tarloxotinib bromide
CAS:<p>Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.</p>Fórmula:C24H24Br2ClN9O3Pureza:99.52%Cor e Forma:SolidPeso molecular:681.77Vps34-IN-3
<p>Vps34-IN-3 is a potent, selective, and orally bioavailable inhibitor of VPS34 kinase .</p>Fórmula:C14H20N4O2Cor e Forma:SolidPeso molecular:276.33EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Fórmula:C33H28N6O3SCor e Forma:SolidPeso molecular:588.68PI3kδ inhibitor 1
CAS:<p>PI3kδ inhibitor 1 is a selective inhibitor of PI3Kδ (IC50 of 3.8 nM).</p>Fórmula:C28H33FN6O2Pureza:98%Cor e Forma:SolidPeso molecular:504.60PI4KIIIbeta-IN-11
CAS:<p>PI4KIIIbeta-IN-11 is a PI4KIIIβ inhibitor (mean pIC50=9.1) that can be used to study diseases caused by RNA viruses and Plasmodium falciparum.</p>Fórmula:C33H39N7O3Cor e Forma:SolidPeso molecular:581.71SST0116CL1
CAS:<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Fórmula:C22H31ClN4O6Cor e Forma:SolidPeso molecular:482.96EGFR-IN-149
CAS:<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Fórmula:C16H15N3OSCor e Forma:SolidPeso molecular:297.375NS-062
CAS:<p>NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.</p>Fórmula:C28H30Cl2F2N6O4Cor e Forma:SolidPeso molecular:623.48PF-5177624
CAS:<p>PF-5177624 is a selective and potent PDK1 inhibitor inducing anti-tumor activity in breast cancer cells.</p>Fórmula:C25H25FN8O2Cor e Forma:SolidPeso molecular:488.52GSK-3β inhibitor 25
CAS:<p>GSK-3β inhibitor25 (Compound 6h) exhibits weak inhibitory activity against GSK-3β with an IC50 greater than 100 μM.</p>Fórmula:C16H15NOSCor e Forma:SolidPeso molecular:269.361EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Fórmula:C21H23N3O5Cor e Forma:SolidPeso molecular:397.4244-FPBUA
CAS:<p>4-FPBUA, a semi-synthetic analog of lichen acid, enhances the functionality of cell-based blood-brain barriers (BBB) and increases the transport of β-amyloid (Aβ) in monolayer cells. Additionally, it acts as an inhibitor of mTOR, enhancing cellular autophagy (Autophagy) which can reverse BBB disruption in vivo, making it relevant for research in Alzheimer's disease.</p>Fórmula:C31H23FO7Cor e Forma:SolidPeso molecular:526.51DNA-PK-IN-2
CAS:<p>DNA-PK-IN-2 is an inhibitor of the DNA-PK enzyme complex, useful in cancer research.</p>Fórmula:C20H23N5O3Cor e Forma:SolidPeso molecular:381.43HER2-IN-8
CAS:<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Fórmula:C26H25F2N9O3Cor e Forma:SolidPeso molecular:549.53NSC381467
CAS:<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C20H16O7Cor e Forma:SolidPeso molecular:368.34PD-M6
CAS:<p>PD-M6 is an mTOR PROTAC degrader with a DC50 of 4.8 μM, which facilitates the ubiquitination and degradation of mTOR. It inhibits the proliferation of cancer cell lines HeLa, MCF-7, and HepG2 with IC50 values of 11.3, 2.58, and 3.23 μM, respectively, and induces autophagy. Additionally, PD-M6 specifically targets the degradation of the key protein LAMTOR1 in the mTOR signaling pathway.</p>Fórmula:C30H39N9O6Cor e Forma:SolidPeso molecular:621.69BPI-15086
CAS:<p>BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.</p>Fórmula:C29H33ClN8O4Cor e Forma:SolidPeso molecular:593.08BML-265
CAS:<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Fórmula:C18H15N3O2Cor e Forma:SolidPeso molecular:305.331GSK3β-IN-2
CAS:<p>GSK3β-IN-2 (Compound S01) is an inhibitor of GSK3β with an IC50 of 0.35 nM. It activates the Wnt/β-catenin signaling pathway, promoting neurogenesis and neurite outgrowth. GSK3β-IN-2 reduces tau protein phosphorylation induced by Aβ at the Ser396 site, thereby decreasing neurofibrillary tangles. Furthermore, GSK3β-IN-2 improves Alzheimer's disease symptoms in a zebrafish model.</p>Fórmula:C25H18N4OCor e Forma:SolidPeso molecular:390.437PI3K-IN-37
CAS:<p>PI3K-IN-37 inhibits PI3K α/β/δ (IC50: 6/8/4 nM) and mTOR (IC50: 4 nM).</p>Fórmula:C25H26N6O2Cor e Forma:SolidPeso molecular:442.51DNA-PK-IN-9
<p>DNA-PK-IN-9 (YK6) is a potent DNA-PK inhibitor with an IC50 of 10.47 nM, important in cancer research.</p>Fórmula:C21H21N5O2Cor e Forma:SolidPeso molecular:375.42EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Cor e Forma:SolidEGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Fórmula:C30H35FN6O3Cor e Forma:SolidPeso molecular:546.64NU5455
CAS:<p>NU5455 is a potent DNA-PKcs inhibitor, oral, boosts doxorubicin in liver tumors, amplifies topoisomerase inhibitors, no adverse effects.</p>Fórmula:C34H33N3O5SCor e Forma:SolidPeso molecular:595.71EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Fórmula:C16H16N4O2SCor e Forma:SolidPeso molecular:328.39D-69491 hydrochloride
CAS:<p>D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.</p>Fórmula:C25H26Cl2FN7O3Cor e Forma:SolidPeso molecular:562.42GSK3β-IN-1
CAS:<p>GSK3β-IN-1 (compound 1) is an inhibitor of glycogen synthase kinase-3β (GSK-3β) with an IC50 value of 65 nM, and it is utilized in Alzheimer's disease research.</p>Fórmula:C17H13FN2O4SCor e Forma:SolidPeso molecular:360.36GSK-3β inhibitor 7
<p>GSK-3β inhibitor 7 is a GSK-3β inhibitor (IC50: 5.25 μM).</p>Fórmula:C27H23BrN4O2SCor e Forma:SolidPeso molecular:547.47EGFR-IN-35
CAS:<p>EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.</p>Fórmula:C25H24ClN7O2Cor e Forma:SolidPeso molecular:489.96GSK-3β inhibitor 26
CAS:<p>GSK-3β inhibitor26 (Compound D14) is a GSK-3β inhibitor with an IC50 of 18.23 μM. This compound is applicable in research related to cancer, inflammation, and neurodegenerative diseases.</p>Fórmula:C15H11N3O3Cor e Forma:SolidPeso molecular:281.266Pred17
<p>Pred17 is an effective EGFR inhibitor with potential applications in lung cancer research.</p>Fórmula:C27H22BN3OCor e Forma:SolidPeso molecular:415.29EGFR-IN-126
CAS:<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Fórmula:C28H28BrFN4O3Cor e Forma:SolidPeso molecular:567.45SIK2-IN-3
CAS:<p>SIK2-IN-3 is an orally active selective inhibitor of SIK1/2 with IC50 values of 0.128/0.084 μM. It hinders the phosphorylation of CRTC3 and suppresses the production of pro-inflammatory factors in myeloid cells. Additionally, SIK2-IN-3 alleviates systemic and tissue inflammatory responses in a mouse anti-CD40 colitis model.</p>Fórmula:C23H24N6O2Cor e Forma:SolidPeso molecular:416.48HER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Fórmula:C20H18N4O3SCor e Forma:SolidPeso molecular:394.447GSK-3β inhibitor 6
<p>GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β, with an IC50 value of 24.4 μM.</p>Fórmula:C20H17BrN4Cor e Forma:SolidPeso molecular:393.28GSK-3β inhibitor 20
CAS:<p>GSK-3β inhibitor20 (compound 3A) is an effective inhibitor of GSK-3β, exhibiting an IC50 value of 74.4 nM.</p>Fórmula:C22H21N5O2SCor e Forma:SolidPeso molecular:419.50
